16 active not recruiting. 16 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 16 | Active not recruiting 16 |
Follow Lung Diseases, Obstructive: new trials by email Literature Review of Lung Diseases, Obstructive trials Research Report on Lung Diseases, Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Rehabilitation and Supplementation With Hydrolyzed Collagen vs. Whey Protein on the Cardiopulmonary, Renal, Muscular, and Immunohematological Response of COPD Patients Verisol Collagen 2,5 g/day, Peptech Collagen 2,5 g/day, Peptech Collagen 10 g/day - Collagen Supplementation, Whey Protein | Phase 4 | Active not recruiting | Federal University of São Paulo | 320 | 2024-08-26 | 2025-06-08 |
| Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma dupilumab, Matching Placebo, ICS/LABA - Asthma | Phase 4 | Active not recruiting | Regeneron Pharmaceuticals | 120 | 2024-08-26 | 2026-05-22 |
| Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care Albuterol and budesonide inhalation aerosol - Asthma | Phase 4 | Active not recruiting | AstraZeneca | 1511 | 2024-05-10 | 2026-07-16 |
| Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate, Inhaled corticosteroids/long-acting beta-2 agonists - Asthma | Phase 4 | Active not recruiting | GlaxoSmithKline | 1358 | 2024-04-16 | 2026-10-06 |
| The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM) n-acetylcystine (NAC)+ albuterol, AeroEclipse-VersaPAP System - Asthma, COPD | Phase 4 | Active not recruiting | University of California, San Francisco | 40 | 2024-04-09 | 2026-08-13 |
| REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study Mepolizumab, Spirometry - Asthma | Phase 4 | Active not recruiting | GlaxoSmithKline | 336 | 2024-03-20 | 2025-08-01 |
| Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 Weeks Mepolizumab Injection, Functional Endoscopic Sinus Surgery (FESS). - Chronic Rhinosinusitis with Nasal Polyps, Asthma | Phase 4 | Active not recruiting | Vibeke Backer | 58 | 2023-04-01 | 2025-03-30 |
| Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices Pre-filled syringe, mepolizumab 100 mg/month, Auto-injector pen, mepolizumab 100 mg/month - Asthma | Phase 4 | Active not recruiting | Hospices Civils de Lyon | 20 | 2023-03-09 | 2024-11-18 |
| Atorvastatin Effect on Reduction of COPD Exacerbations Atorvastatin 40 Mg Oral Tablet, Placebo - Copd, COPD Exacerbation | Phase 4 | Active not recruiting | Medical University of Bialystok | 460 | 2022-02-11 | 2026-04-21 |
| Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma Dupilumab, Placebo - Asthma | Phase 4 | Active not recruiting | Sanofi | 1339 | 2021-12-16 | 2026-04-16 |
| Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic Pain SCS Device Program Setting - Chronic, Intractable Back Pain and/or Leg Pain | Phase 4 | Active not recruiting | Nevro Corp | 25 | 2021-11-16 | 2026-06-29 |
| Investigating Dupilumab's Effect in Asthma by Genotype Dupilumab, Placebo - Asthma | Phase 4 | Active not recruiting | Boston Children's Hospital | 150 | 2021-09-08 | 2026-02-23 |
| Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics Benralizumab, Placebo - Asthma | Phase 4 | Active not recruiting | AstraZeneca | 75 | 2019-10-08 | 2026-09-25 |
| Secondhand Smoke Respiratory Health Study Albuterol, Placebo - Secondhand Smoke, Air Trapping | Phase 4 | Active not recruiting | University of California, San Francisco | 107 | 2016-06-06 | 2026-06-04 |
| RELVAR Effects on Parasternal Muscle Activity, Diaphragm, and Ventilation in Severe COPD Ventilation, Parasternal EMG, Phrenic magnetic stimulation - Copd | Phase 4 | Active not recruiting | University of Calgary | 30 | 2016-04-01 | 2025-02-18 |
| CINC424A2X01B Rollover Protocol ruxolitinib, panobinostat - Primary Myelofibrosis, Polycythemia Vera | Phase 4 | Active not recruiting | Novartis Pharmaceuticals | 279 | 2015-03-05 | 2026-10-19 |
Asthma (10) · Pulmonary Disease, Chronic Obstructive (4) · Bronchiolitis Obliterans Syndrome (2) · Graft vs Host Disease (1) · Leukemia, Myeloid, Acute (1) · Lung Diseases (1) · Pneumonia (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1) · Pulmonary Eosinophilia (1) · Smoking (1) · Thalassemia (1)
Respiratory Tract Diseases (16) · Lung Diseases (15) · Bronchial Diseases (12) · Immune System Diseases (12) · Hypersensitivity (10) · Hypersensitivity, Immediate (10) · Respiratory Hypersensitivity (10) · Chronic Disease (4) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Bronchiolitis (2) · Bronchiolitis Obliterans (2) · Bronchitis (2)
dupilumab (3) · mepolizumab (3) · Albuterol (2) · Acetylcysteine (1) · Atorvastatin (1) · Fluticasone (1) · N-monoacetylcystine (1) · Panobinostat (1) · Procaterol (1) · Propionates (1) · Resistance Training (1) · Tablets (1) · Ventilation (1) · benralizumab (1) · fluticasone furoate (1)
AstraZeneca (2) · GlaxoSmithKline (2) · University of California, San Francisco (2) · Boston Children's Hospital (1) · Federal University of São Paulo (1) · Hospices Civils de Lyon (1) · Medical University of Bialystok (1) · Nevro Corp (1) · Novartis Pharmaceuticals (1) · Regeneron Pharmaceuticals (1) · Sanofi (1) · University of Calgary (1) · Vibeke Backer (1)
United States (10) · Canada (7) · Poland (4) · Belgium (3) · China (3) · Denmark (3) · France (3) · Germany (3) · Japan (3) · South Korea (3) · Australia (2) · Brazil (2) · Bulgaria (2) · Greece (2) · Hungary (2)
Gilles Devouassoux, Pr (1) · John Fahy, MD, MS (1) · Mario Castro, MD (1) · Mayank Gupta, MD (1) · Mehrdad Arjomandi, MD (1) · Paul A Easton, MD, PhD (1) · Vibeke B Backer, Professor (1) · Wanda Phipatanakul, MD, MS (1)
PMID 36891077, PMID 42474701, PMID 42492489, PMID 42742633
2014 (1), 2018 (1), 2023 (1), R01HL080414 (1), U01AI143514 (1)